Navigation Links
ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Date:6/15/2011

EXTON, Pa., June 15, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.  The approval also includes a self administration option for appropriately trained patients included in the Summary of Product Characteristics (SPC).

The therapeutic indication in Europe is for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment.

"Many patients experience frequent or severe attacks that are not only disabling and potentially fatal, but also lead to constant anxiety about when an attack will occur significantly impacting patients' ability to conduct normal and productive lives," commented Prof. Konrad Bork of the Department of Dermatology of Johannes Gutenberg University in Mainz, Germany. "The approval of Cinryze in Europe provides a very important new option to meet the needs of these severely afflicted HAE patients."

Privatdozent Wolfhart Kreuz, M.D., of the Comprehensive Care Centre (CCC) for Hereditary and Acquired Angioedema of Johann Wolfgang Goethe University Hospital in Frankfurt, Germany added, "While it is essential that we provide therapies to treat HAE attacks, many patients require or want the ability to proactively reduce the frequency or severity of their attacks.  Cinryze is a comprehensive manage
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
2. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
3. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
7. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
10. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014  Relmada ... therapies for the treatment of chronic pain, announced today ... Sloan Kettering Cancer Center (MSKCC) in a series of ... ER, a new tamper-resistant, extended release form of levorphanol. ... investigator for these studies. Dr. Pasternak ...
(Date:9/15/2014)... NEW YORK , Sept. 16, 2014 ... Neuropathy Foundation (HNF) announced today an agreement to collaborate ... disease and support the development of a stronger CMT ... provide financial support to several HNF,s initiatives including: ... section in the HNF website featuring  HNF newsletters, materials ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics ... specialty pharmaceutical company with a focus on Omega-3 ... today that the Board of Directors approved the ... an advisor at the close of business on Friday, ... of 1,000,000 common shares of the Company were ...
Breaking Medicine Technology:Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Pivotal Therapeutics Grants Incentive Stock Options 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 2FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 3FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 4FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 5FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 6FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 7FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 8FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 9FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 10FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 11Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 2Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 3Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 4Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 5Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 6
(Date:9/16/2014)... September 16, 2014 Wholelifeinsurancecompanies.org has released ... find life insurance with a bad heart condition. , ... find affordable life insurance if they compare quotes. Most ... the decision depend on the actual and past medical ... that caused several heart attacks in the past, his ...
(Date:9/16/2014)... positron emission tomography (PET) tracer is effective in diagnosing ... according to a case study conducted at the Icahn ... Neuroimaging (MNI) LLC in New Haven, and published September ... Specifically, the study results suggest that an experimental radiolabeled ... onto a protein called tau that accumulates in the ...
(Date:9/16/2014)... soon better predict a man,s risk of getting prostate ... the largest-ever analysis of the cancer,s genetic biomarkers, reported ... of Health and Biomedical Innovation,s Dr Jyotsna Batra and ... in the large consortia of research hubs around the ... genetic markers in 80,000 men. , "It,s the largest ...
(Date:9/16/2014)... York, NY (PRWEB) September 16, 2014 ... in diagnosing concussion-related brain disease while a person is ... the Icahn School of Medicine at Mount Sinai, and ... published September 16 in the journal Translational Psychiatry. , ... compound called [18 F]-T807, which is designed to latch ...
(Date:9/16/2014)... 16, 2014 The Muscular Dystrophy ... flu vaccines for individuals affected by muscle disease, ... other neuromuscular diseases. , MDA offers this service ... disease who, because of compromised respiratory function — ... lungs — are at increased risk of serious ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4Health News:MDA Offers Flu Shots to Those Affected by Muscle Disease 2
... and vegetable juice could stave off Alzheimer's disease, say ... in the skin and peels of fruits and vegetables. ... ,Lab trials have earlier shown that polyphenols can ... to significantly delay the onset of serious cognitive impairment. ...
... silent killer worldwide and it is imperative to make people aware ... to be taken, say medical experts.// ,Now in its third ... to increase awareness about hepatitis B and C. The theme for ... silent disease. Most of the people are unaware that they have ...
... economic, social and health factors affecting African Americans, Penn ... Black’//. , ,Dr. Shaun Gabbidon, associate professor of ... and public policy, both at Penn State's Harrisburg campus, ... the Journal of Black Studies. , ,"There are ...
... among eighty countries has found that the Iraqi public portrays ... // out-groups. Ethnic solidarity seems to be at an all ... on restoration of order and security, along with emergence of ... embittered and torn Iraqi nation. The analysis is an outcome ...
... starches and sugars with unhealthy high-fat foods? A new ... ,A recent study of an internet-based support ... for dieters on low-carbohydrate diets has been the addition ... carbohydrates removed from their diet. The report was published ...
... antibiotic shows early promise as an anti-cancer agent, inhibiting ... tumors, // according to researchers at the University of ... appear in the Oct. 1 issue of Cancer Research. ... to be over-expressed in cancer cells to screen for ...
Cached Medicine News:Health News:Awareness Must to Tackle Hepatitis: Experts 2Health News:Understanding Stress Triggers for African Americans 2Health News:Iraqi’s Gripped with Insecurit 2Health News:Iraqi’s Gripped with Insecurit 3Health News:Low-Carb Dieters Eat More Vegetables 2Health News:Antibiotic Inhibits Cancer Gene Activity 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: